Cardio Diagnostics (CDIO) Stock Price, News & Analysis

Company Overview

Cardio Diagnostics Holdings, Inc. is a biotechnology and medical technology company focused on the prevention and early detection of cardiovascular disease. The company combines artificial intelligence with genetic and epigenetic data to develop personalized tools intended to help identify cardiovascular risk and support more targeted care.

Its products include Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease, and PrecisionCHD, which is intended to help identify the presence of coronary heart disease. The company’s testing platform is designed to provide physicians with information that may support earlier intervention and individualized prevention strategies.

Founded in 2017, Cardio Diagnostics is headquartered in Chicago and serves the healthcare market through physician-ordered testing and related clinical services. The company was co-founded by Meesha Dogan, who has served as its chief executive officer, and uses its technology to address cardiovascular disease prevention and management.

Key Stats

• Today's Range: $1.89 to $1.97
• 50-Day Range: $1.55 to $2.21
• 52-Week Range: $0.97 to $7.91
• Volume: 38,594 shs
• Average Volume: 31,767 shs
• Market Capitalization: $5.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Cardio Diagnostics Stock Analysis - MarketRank™

Cardio Diagnostics scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Cardio Diagnostics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Cardio Diagnostics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cardio Diagnostics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cardio Diagnostics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cardio Diagnostics has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.20% of the float of Cardio Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Cardio Diagnostics has a short interest ratio ("days to cover") of 0.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardio Diagnostics has recently decreased by 77.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardio Diagnostics does not currently pay a dividend.

Dividend Growth

Cardio Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.19

News Sentiment

Cardio Diagnostics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cardio Diagnostics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardio Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.99% of the stock of Cardio Diagnostics is held by insiders.

Percentage Held by Institutions

8.06% of the stock of Cardio Diagnostics is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CDIO
• CIK: 1870144
• Web: www.cdio.ai
• Phone: (855) 226-9991
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.50 million
• Net Margins: -43,133.33%
• Pretax Margin: -43,126.66%
• Return on Equity: -82.28%
• Return on Assets: -76.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.16
• Quick Ratio: 17.16

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 577.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.82 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 2,960,000
• Free Float: 2,694,000
• Market Cap: $5.77 million
• Optionable: Not Optionable
• Beta: 2.28